Ensysce Biosciences, INC 10-Q quarterly reports

Ensysce Biosciences reports continued net losses and substantial doubt regarding its going concern status, despite progress in clinical trials and a recent acquisition.

Ensysce Biosciences reported a significant increase in net loss and cash burn for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Ensysce Biosciences, a clinical-stage biotech, reported significant operating losses in Q3 2025 and for the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Ensysce Biosciences reported a reduced net loss in Q2 2025, driven by increased grant funding and R&D activities, but faces substantial doubt about its ability to continue as a going concern without further capital.

Ensysce Biosciences' Q1 2025 shows increased grant revenue and reduced net loss compared to Q1 2024, but the company still faces substantial doubt about its ability to continue as a going concern.

Ensysce Biosciences saw a significant increase in federal grant revenue and completed multiple equity raises in Q3 2024, while research and development expenses decreased.

Ensysce Biosciences reported its financial results for the second quarter of 2024, highlighting ongoing research and development activities and the need for additional funding.

Ensysce Biosciences reported its financial results for the first quarter of 2024, highlighting ongoing research and development efforts and recent financing activities.